Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2425

Sigma-Aldrich

Manidipine hydrochloride

≥98% (HPLC)

Synonym(s):

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid hydrchloride, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester, 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrchloride, CV 4093 hydrchloride, CV-4093 hydrchloride, CV4093 hydrchloride, Franidipine hydrchloride, Manidipine 6300 hydrchloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C35H38N4O6 · xHCl
CAS Number:
257288-11-2
Molecular Weight:
610.70 (free base basis)
MDL number:
MFCD00871291
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

Biochem/physiol Actions

Manidipine is a dihydropyridine class calcium channel blocker (CCB) that exerits its antihypertensive activity via targeting both L-type and T-type calcium channels. In contrary to other dihydropyridines and non-dihydropyridines that mainly act as L-type CCBs, Manidipine diminishes glomerular pressure and, consequently, albumin excretion via its action against T-type channels of efferent arterioles in addition to promoting afferent arteriole dilation by blocking L-type channels. Clinically, Manidipine is as effective in lowering blood pressure as other dihydropyridines, while only Manidipine significantly reduces albuminuria and insulin resistance with less adverse effects. In obese and hypertensive individuals, Manidipine is more effective than Lercanidipine in reducing insulin resistance, while Nifedipine treatment is reported to increase insulin desensitisation.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301,H336

Hazard Classifications

Acute Tox. 3 Oral - STOT SE 3

Target Organs

Central nervous system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Margarita Saiz-Satjes et al.
Future cardiology, 13(2), 143-151 (2016-11-26)
In AMANDHA trial, the addition of manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions. Factors associated with
H Nakaya et al.
European journal of pharmacology, 146(1), 35-43 (1988-01-27)
The effects of CV-4093, a new dihydropyridine derivative, on isolated cardiovascular tissues were compared with those of several dihydropyridine and non-dihydropyridine calcium antagonists. CV-4093 effectively inhibited the contractions induced in canine femoral arteries by high [K+]0 and Bay K 8644
K Okabe et al.
The Journal of pharmacology and experimental therapeutics, 243(2), 703-710 (1987-11-01)
Effects of CV-4093, a newly synthesized dihydropiridine type of Ca antagonist, on membrane currents in enzymatically dispersed single smooth muscle cells of the rabbit main pulmonary artery were investigated using the single electrode voltage clamp method. Three types of membrane
Y Shibouta et al.
Japanese journal of pharmacology, 48(4), 463-472 (1988-12-01)
The calcium-channel blocking action of franidipine (CV-4093.2HCl) was investigated in vitro and in vivo. CV-4093.2HCl inhibited the 60 mM K+-induced contraction of rabbit aorta and those of coronary, renal, mesenteric and femoral arteries of dog less potently than nifedipine and
Margarita Saiz Satjes et al.
Future cardiology, 12(4), 435-447 (2016-05-26)
Renin-angiotensin system inhibitors should be considered as the first-line therapy in the treatment of patients with hypertension and diabetes. However, most of the diabetic subjects with hypertension require at least two drugs to achieve blood pressure targets. The ACCOMPLISH trial
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service